PDCD1 and lung carcinoma: The synergistic effect of nintedanib and anti-PD-1 therapy on lung cancers was revealed in in vitro and in vivo experiments (45); significantly increased ICI therapy responses, relieved aggravated lung injuries, inhibited tumor metastasis, and activated tumor immune microenvironment were observed (46).